Strides Strengthens Anti-Inflammatory Portfolio with USFDA Approval for Celecoxib Capsules, 100 mg, 200 mg, and 400 mg

Strides Pharma Science Limited CIN: L24230MH1990PLC057062 Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India Tel: +91-80-6784 0000 Fax: +91 80 6784 0700 Regd Off: ‘Cyber One’, Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703, India Tel:+91-22-2789 2924/ 3199 [email protected]; www.strides.com April 30, 2025 BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip code: 532531 The National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex Bandra (E) Mumbai - 400 051 Scrip code: STAR Dear Madam/ Sir, Sub: Press Release Please find attached Press Release issued by the Company titled: “Strides Strengthens Anti-Inflammatory Portfolio with USFDA Approval for Celecoxib Capsules, 100 mg, 200 mg, and 400 mg” Thanks & Regards, For Strides Pharma Science Limited, Manjula Ramamurthy Company Secretary ICSI Membership No. A30515 Encl. As above Press Release April 30, 2025 Strides Strengthens Anti-Inflammatory Portfolio with USFDA Approval for Celecoxib Capsules, 100 mg, 200 mg, and 400 mg ▪ Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base Bangalore, India, April 30, 2025 - Strides Pharma Science Limited (Strides) today announced that its step - down wholly owned subsidiary , Strides Pharma Global Pte. Limited, Singapore, has received approval for Celecoxib Capsules, 100 mg, 200 mg, and 400 mg, from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Celebrex® Capsules, 100 mg, 200 mg, and 400 mg, of Upjohn US 2 LLC. The approval of Celecoxib Capsules strengthens Strides’ portfolio in the anti -inflammatory therapeutic segment. This approval complements the company’s existin g products in the same therapy area and enhances its ability to serve a broader patient population with effective, affordable treatment options. Celecoxib is a selective COX-2 inhibitor used for the management of pain and inflammation associated with various conditions including osteoarthritis, rheumatoid arthritis, acute pain, and dysmenorrhea. Celecoxib Capsules, 100 mg, 200 mg, and 400 mg have a combined market size of ~US$ 116 Mn as per IMS. The product will be manufactured at the company’s facility in Puducherry. About Celecoxib Capsules Celecoxib is a nonsteroidal anti -inflammatory drug (NSAID) that works by reducing hormones that cause inflammation and pain in the body. It is commonly prescribed to manage symptoms of arthritis, pain, and other inflammatory conditions. About Strides Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR) . The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy and an institutional business to service donor - funded markets. The Company’s global manufa cturing sites are located in India (Chennai, Puducherry , and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi) , and the United States (New York). The Company focuses on “difficult to manufacture” products sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com. For further information, please contact: Institutional Investors Vikesh Kumar Group CFO [email protected] Saurabh Ambaselkar Investor Relations +91 99609 31220 [email protected] Strides Pharma Science Limited CIN: L24230MH1990PLC057062 Corp. Office: Strides House, Bannerghatta Road, Bengaluru – 560076 Corporate Communication Pallavi Panchmatia: +91 80 6784 0193 [email protected] PR Consultancy Adfactors PR Janhavi Bellare: +91 93228 54508 [email protected] Talal Syed: +91 99876 19679 [email protected]

The release as fetched from its publisher. strides.com ↗